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Introduction: In patients with resected lung cancer, sarcomatoid 
carcinomas are reputed to carry a worse prognosis. Although gener-
ally felt to be chemo-refractory, little data are available about che-
motherapy in these patients. We sought to determine the effect of 
perioperative chemotherapy in patients with completely resected sar-
comatoid carcinomas of the lung.
Methods: We reviewed the pathology reports of 4675 patients consec-
utively resected at Memorial Sloan-Kettering between 2000 and 2010. 
Charts and images were reviewed for patients with a histologic diagno-
sis of sarcomatoid carcinoma. Response to neoadjuvant chemotherapy 
was assessed radiographically. Kaplan–Meier disease-free probability 
(DFP) curves were compared for patients who did and did not receive 
perioperative chemotherapy, stratified by pathological stage.
Results: Of the 4675 patients who underwent an R0 lung cancer 
resection, 56 (1%) were diagnosed with sarcomatoid carcinomas. 
Twenty received neoadjuvant and/or adjuvant chemotherapy. Overall 
radiographic response rate (minor + major) to neoadjuvant che-
motherapy was 73% (95% confidence interval 48–90%) in the 15 
evaluable patients. The median DFP of patients who received che-
motherapy was 34 months versus 12 months in those who did not 
(p = 0.37). Subset analysis did not reveal a benefit to perioperative 
chemotherapy in patients with stage Ib–IIa, whereas a benefit was 
seen in patients with IIb–IIIa disease (p = 0.02).
Conclusions: Although sarcomatoid carcinomas are felt to be 
chemo-refractory, our results demonstrate radiographic responses to 
neoadjuvant chemotherapy and an improvement in DFP in patients 
with stage IIb–IIIa disease. The use of pathological stage in this 
analysis may underestimate this benefit. Perioperative chemotherapy 
should be considered in these patients.
Key Words: Pulmonary sarcomatoid carcinoma, Non–small-cell 
lung cancer, Adjuvant chemotherapy, Neoadjuvant chemotherapy.
(J Thorac Oncol. 2012;7: 1400–1405)
In completely resected non-small cell lung cancers (NSCLCs), postoperative cisplatin-based chemotherapy 
has been shown to improve overall survival in multiple 
large, randomized clinical trials.1,2 Early trials of neoad-
juvant chemotherapy in stage IIIa disease also showed 
improvement in disease-free and overall survival.3 Studies 
of neoadjuvant chemotherapy in earlier-stage disease were 
either underpowered to show a survival benefit, or closed 
early when the previously mentioned data on adjuvant ther-
apy were appreciated.4,5 A meta-analysis has demonstrated 
a survival benefit with neoadjuvant chemotherapy similar 
to that observed in studies of adjuvant chemotherapy for 
stages Ib–IIIa NSCLCs.6
Historically, clinical trials in both advanced and resect-
able lung cancers have been designed to treat NSCLCs, regard-
less of pathologic subclassifications. In the past decade, it has 
become evident that pathologic and molecular subgroups 
are critical in selecting therapy. These relevant therapeu-
tic advances include the identification of somatic oncogenic 
driver mutations in more than 50% of patients with adeno-
carcinomas,7 the superiority of pemetrexed over gemcitabine 
in the nonsquamous subset of NSCLCs,8 and the safety of 
bevacizumab in patients with squamous cell carcinomas.9 This 
increasing attention to histology, both in clinical practice and 
in trial design, has brought to light the less common lung can-
cers such as large cell carcinomas, large cell neuroendocrine 
carcinomas, NSCLCs not otherwise specified, and sarcoma-
toid carcinomas.
The lung cancers collectively referred to as sar-
comatoid carcinomas include a spectrum of pulmonary 
malignancies that total approximately 1% of NSCLCs.10 
Despite this small percentage, this group accounts for more 
than 2000 diagnoses per year in the United States alone. 
Histologically, the category of sarcomatoid carcinoma is a 
group of poorly differentiated NSCLCs that is either pleo-
morphic or contains sarcomatoid or spindle cell compo-
nents. This includes pleomorphic carcinomas, spindle cell 
carcinomas, giant cell carcinomas, carcinosarcomas, and 
pulmonary blastomas.11
Clinically, sarcomatoid carcinomas are generally 
considered to portend a poor prognosis.12,13 At presentation, 
tumors are often large and either centrally invasive of the 
proximal airways and vessels or peripherally invasive of 
the chest wall.14,15 Treatment revolves around surgical 
management, although outcomes are worse than in other lung 
cancers.16–18 Data in advanced disease suggest that sarcomatoid 
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carcinomas rarely respond to systemic chemotherapy.19 Clinical 
trials of perioperative chemotherapy in resected NSCLCs 
have not reported on treatment benefit in this subgroup. 
To our knowledge, no systematic reports of perioperative 
chemotherapy in this rare subset of NSCLCs have been 
published. We therefore sought to determine the effect of 
perioperative chemotherapy on disease-free survival in patients 
with resectable sarcomatoid carcinomas of the lung, with the 
secondary objective of evaluating radiographic responses.
PATIENTS AND METHODS
Of the 4675 patients who underwent a complete (R0) 
resection for primary lung cancer between 2000 and 2010 
at Memorial Sloan-Kettering Cancer center, we identified 
56 patients (1%) with sarcomatoid lung cancers. Histology 
was based upon the World Health Organization classifica-
tion of sarcomatoid carcinoma defined at the time of surgical 
resection.11,20
Clinical information was compiled from the medi-
cal record. The final pathological staging was assigned 
based on the American Joint Committee on Cancer 7th 
edition tumor-node-metastasis staging system.21 Available 
computed tomography (CT) images were reviewed by a 
dedicated thoracic radiologist. This review was unbiased, 
without radiologist knowledge of treatment history or goals 
of the image review. Response to neoadjuvant chemo-
therapy was determined by bidimensional primary tumor 
measurements per World Health Organization, which cat-
egorizes response as minor or major, 25% or 50% decrease 
in product of the diameters, respectively.22,23 Response 
Evaluation Criteria In Solid Tumors responses are listed for 
comparison.
All reviews were carried out under Institutional Review 
Board/Privacy Board—approved waivers. The clinical charac-
teristics of patients who received and did not receive neoad-
juvant therapy were compared using Wilcoxon sign-rank test 
(for continuous variables) and Fisher’s exact test (for categori-
cal variables). Disease-free probability (DFP) was calculated 
from date of surgery. Patients were followed until recurrence, 
or censored at the date of death or last contact. DFP was cal-
culated by the Kaplan–Meier method and compared across 
groups using the log-rank test. All statistical analyses were 
carried out using SAS statistical software (SAS Institute, 
Cary, NC).
RESULTS
Of the 4675 patients who underwent a R0 resection 
for primary lung cancer, 56 (1%) were classified as having 
sarcomatoid carcinomas. The baseline patient characteris-
tics, including pathological stage and surgical procedure, 
are listed in Table 1. Of the 38 patients with preoperative 
biopsies, only three patients (8%) were identified with 
spindle and/or giant cell features. In the remaining cases, 
the preoperative diagnoses were non–small-cell carcinoma 
TABLE 1. Baseline Patient Characteristics
Characteristic
All Patients 
(N = 56)
Perioperative Chemotherapy 
(n = 20)
No Chemotherapy 
(n = 36) p
Age (yrs) 70 (42–87) 66 (42–76) 72 (46–87) <0.001
Sex
 Female 31 (55%) 10 (50%) 21 (58%) 0.59
 Male 25 (45%) 10 (50%) 15 (42%)
Smoking history
 Former/current 45 (80%) 17 (85%) 28 (78%) 0.73
 Never 11 (20%) 3 (15%) 8 (22%)
Pathological stage
 Ia 11 (20%) 2 (10%) 9 (25%) 0.26a
 Ib 12 (21%) 4 (20%) 8 (22%)
 IIa 11 (20%) 4 (20%) 7 (19%)
 IIb 14 (25%) 5 (25%) 9 (25%)
 IIIa 8 (14%) 5 (25%) 3 (8%)
Chemotherapy
 Adjuvant 5 (9%) 5 (25%) 36 (100%)
 Neoadjuvant 17 (30%) 17 (85%)
 None 36 (64%)
Surgical procedure
 Wedge/segmentectomy 8 (14%) 1 (5%) 7 (19%) 0.02b
 Lobectomy 42 (75%) 14 (70%) 28 (78%) 0.41c
 Pneumonectomy 6 (11%) 5 (25%) 1 (3%)
aComparison of stages Ia–IIa versus IIb–IIIa.
bComparison of all surgical procedures.
cComparison of wedge/segmentectomy with lobectomy.
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(n = 11), adenocarcinoma (n = 13), squamous cell carci-
noma (n = 9), large cell carcinoma (n = 1), and large cell 
neuroendocrine carcinoma (n = 1). Of note, 16 patients 
(29%) had multifocal disease with a synchronous primary 
of alternative histology. All synchronous primaries were 
stage Ia and were invasive adenocarcinomas or adenocar-
cinoma with a lepidic component These synchronous pri-
maries occurred with seven stage 1a, three stage Ib, two 
stage IIa, three stage Iib, and one stage IIIa sarcomatoid 
carcinomas, and all were completely resected.
Twenty patients (36%) received perioperative che-
motherapy including 17 neoadjuvant and five adjuvant (2 
patients received both). Patients who received neoadjuvant 
chemotherapy tended to be younger than those who did not 
(p < 0.001). In the 17 patients who received neoadjuvant 
chemotherapy, the diagnosis of sarcomatoid carcinoma was 
suspected based on pretreatment cytology or small biopsy in 
three cases (18%). In the remaining patients, the diagnoses 
were five unclassified NSCLCs, four adenocarcinomas, four 
squamous cell carcinomas, and one large cell neuroendo-
crine carcinoma. All but one patient received a cisplatin or 
carboplatin-based doublet regimen either preoperatively or 
postoperatively. One patient with a documented EGFR exon 
19 deletion received neoadjuvant erlotinib in combination 
with pemetrexed. Four of the 17 patients who received neo-
adjuvant chemotherapy did so with concurrent radiation 
therapy—one for a pancoast tumor and three treated with 
neoadjuvant chemoradiation at other institutions.
Objective responses to neoadjuvant chemotherapy and 
chemoradiation were evaluable in 15 of the 17 patients who 
received preoperative therapy. Four patients had a minor 
response and seven patients had a major response to induc-
tion therapy, six with chemotherapy and one with concurrent 
chemoradiotherapy. The evaluable chemotherapy regimens 
and best responses are listed in Table 2. A representative 
example of pre- and post-treatment CT images from a patient 
who received neoadjuvant cisplatin and docetaxel is presented 
in Figure 1.
With a median follow-up of 12 months, 28 patients 
(50%) had recurrences with a median DFP of 13 months. 
Seven of the patients who had recurrences had a synchro-
nous stage Ia adenocarcinoma. Recurrence was confirmed to 
be of sarcomatoid histology in five of the seven; the other 
two patients had recurrences within 3 months of the resection 
of their sarcomatoid carcinoma and did not undergo repeat 
biopsy. The median DFP was 12 months in the patients who 
did not receive perioperative chemotherapy and 34 months 
in the patients who did receive perioperative chemotherapy 
(Fig. 2). This difference did not reach statistical significance 
(p = 0.37). In a subgroup analysis, the difference in DFP was 
statistically significant in favor of perioperative chemother-
apy in pathologic stage IIb–IIIa patients (p = 0.02) but not in 
pathologic stage Ib–IIa patients (p = 0.82) (stage IA p = 0.6, 
stage IB p = 0.33, and stage IIA p = 0.43). Kaplan–Meier 
DFP curves for the stage IIb–IIIa cohort are depicted in 
Figure 3. Despite the heterogeneous patient population, sex, 
smoking status, and pneumonectomy versus a lesser surgi-
cal resection did not have a statistically significant impact on 
recurrence-free probability, unadjusted, or when adjusted for 
stage (Table 3).
Of the 28 patients with recurrence, 15 patients had 
recurrences with local disease only, five had recurrences 
with both local and distant disease, and eight had recurrences 
with distant disease only. The pattern of recurrence was not 
different in those who did and did not receive perioperative 
chemotherapy. Sites of distant disease included brain 
TABLE 2.  Neoadjuvant Regimens and Responses by WHO 
and RECIST
Regimen N
WHO Response RECIST  
Partial  
ResponseMinor Major
Cisplatin + docetaxel 8 3 3 3
Carboplatin + paclitaxel 3 1 1 1
Cisplatin + gemcitabine 1 1 1
Pemetrexed + erlotinib 1 1 0
Carboplatin + paclitaxel + 
radiotherapy
1 0 0 0
Cisplatin + etoposide + 
radiotherapy
1 1 1
Total 15 4 (27%) 7 (47%) 6 (40%)
WHO, World Health Organization; RECIST, Response Evaluation Criteria In Solid 
Tumors.
FIGURE 1.  A 55year-old woman, cur-
rent smoker, diagnosed preoperatively 
with pleomorphic carcinoma (adeno-
carcinoma and clear cell features) 
based on biopsy. Baseline CT shown in 
(A) demonstrates a large right upper 
lobe lobular mass. She received three 
cycles of neoadjuvant cisplatin and 
docetaxel with post-treatment CT scan 
shown in (B) demonstrating substan-
tial decrease in size. CT, computed 
tomography.
1403Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 7, Number 9, September 2012 Perioperative Chemo in Pulmonary Sarcomatoid Carcinomas 
(n = 4), adrenal (n = 4), bone (n = 2), liver (n = 1), and 
skin/subcutaneous tissue (n = 3). Of the 28 patients who 
had recurrences, 11 were treated with chemotherapy, five 
of these had been treated previously with perioperative 
chemotherapy. There was one objective response out of six 
patients treated with a cisplatin or carboplatin-based doublet. 
The patient who responded at the time of disease recurrence 
had not received perioperative chemotherapy. There were 
no responses to single-agent therapy. The only patient who 
received bevacizumab developed hemoptysis. Of the 28 
patients who had recurrences, 22 died of their recurrent 
sarcomatoid carcinoma. The median time from recurrence to 
death was 3 months (range, 1–21 months).
DISCUSSION
Our series confirms that sarcomatoid carcinoma 
accounts for approximately 1% of all surgically resected 
NSCLCs. Interestingly, of the 56 patients with sarcomatoid 
carcinomas, 16 (29%) had synchronous stage Ia NSCLCs 
with glandular differentiation. Those with two primary lung 
cancers had a higher cumulative tobacco use than those 
without (median 50 versus 32 pack-years), but there was no 
statistical difference in the number of smokers versus never 
smokers. Forty-five of 56 patients in this series had path-
ological stage Ib–IIIa and therefore meet criteria for peri-
operative chemotherapy, either neoadjuvant or adjuvant.24 
Perhaps because of the time of surgery relative to the litera-
ture supporting perioperative chemotherapy, other comor-
bid conditions, or the reputation for chemoresistance in this 
patient population, only 20 of the 45 eligible patients in this 
series received perioperative chemotherapy. Although one 
may hypothesize that neoadjuvant chemotherapy may select 
for sarcomatoid histology in the residual tumor, the fact that 
the majority of the patients in this series did not receive neo-
adjuvant chemotherapy makes this difficult-to-test theory 
unlikely.
We set out to evaluate the impact of perioperative 
chemotherapy on disease-free survival and responses to 
neoadjuvant chemotherapy in the evaluable subset. We chose 
pathological stage as the categorical variable for analysis as 
clinical stage was not systemically evaluable in all patients. 
Given the heterogeneous patient population with multiple 
medical comorbidities that were not uniformly documented, 
disease-free survival and not overall survival was considered 
to be the endpoint more representative of treatment effect. 
It is worth noting that the usage of pathological stage may 
minimize the benefit of neoadjuvant chemotherapy because 
patients who receive neoadjuvant therapy tend to have a higher 
clinical stage, and if they are downstaged they are included in 
the lower-risk group and compared directly with patients who 
have earlier-stage disease. We found that 11 of the 15 patients 
who received neoadjuvant chemotherapy and had CT images 
available for review had objective responses. Furthermore, 
patients with pathological stage IIb–IIIa who received 
perioperative chemotherapy had a significant improvement in 
disease-free survival.
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FIGURE 2.  Disease-free survival in all patients who did and 
did not receive perioperative chemotherapy.
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FIGURE 3.  Disease-free survival in patients with pathological 
stage IIb and IIIa, who did and did not receive perioperative 
chemotherapy.
TABLE 3.  Two-year Recurrence-Free Probability by Clinical 
Variable
Variable
2-Year 
Recurrence-Free 
Probability (%)
95% 
Confidence 
Interval
Unadjusted  
p
p  
Adjusted 
for Stage
Sex 0.26 0.57
Female 54 37–79
Male 43 26–69
Smoking 0.72 0.53
Never 50 25–100
Former/current 49 35–67
Pneumonectomy 52 38–70 0.65 0.48
Other resection 33 11–100
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There are obvious limitations and potential biases in this 
analysis. We cannot clearly determine what led physicians to 
choose to administer perioperative chemotherapy to some 
patients and not others. The group that received chemotherapy 
had significantly younger patients with fewer comorbid 
conditions, perhaps influencing this decision, whereas nearly 
half of the group that did not receive chemotherapy had stage 
I disease. The rate of sublobar resections was not statistically 
different than that of lobectomy in the two groups, and five of 
seven sublobar resections in the patients who did not receive 
chemotherapy were performed for stage I disease, a stage in 
which no benefit was seen with chemotherapy. Among the 
patients with higher stages of the disease, those who did not 
receive chemotherapy may have been predisposed to disease 
recurrence because of fewer pneumonectomies, though all 
resection specimens had pathologically negative margins 
and four of the five patients who underwent pneumonectomy 
and received perioperative chemotherapy had recurrences, 
negating the potential impact of more extensive resection in the 
chemotherapy group on the study findings.
The literature is devoid of clinical trial data on sarcoma-
toid carcinomas of the lung, and treatment recommendations 
are based entirely on small case-series reports. One of the chal-
lenges is the difficulty in preoperative diagnosis as we found 
the diagnosis of sarcomatoid carcinoma was suspected in only 
8% of all cases that were biopsied and in 18% of those that 
received neoadjuvant therapy. The only prior report of resect-
able sarcomatoid carcinomas in which adjuvant (but not neo-
adjuvant) chemotherapy was reported is a 20-patient series in 
which 14 patients with lymph node positive disease received 
adjuvant cisplatin and gemcitabine. None of the six lymph node 
negative patients received chemotherapy. Although the two 
groups were not compared, the median disease-free survival 
of the entire cohort was only 5 months and overall survival 8 
months. The authors concluded that this disease is not chemo-
therapy sensitive.17 Additional surgical case-series reports have 
been published describing poor outcomes, though few patients 
received either adjuvant or neoadjuvant chemotherapy.16,18 The 
data on chemotherapy in advanced disease is equally discour-
aging, with no objective responses seen in 13 sequentially 
treated patients with metastatic sarcomatoid carcinomas.19
Our findings differ from the literature, with both objec-
tive responses to neoadjuvant chemotherapy and improvement 
in disease-free survival observed in patients with resectable 
stage IIb–IIIa sarcomatoid carcinoma of the lung who are 
treated with perioperative chemotherapy. Although we did not 
see a benefit to perioperative chemotherapy in earlier stage dis-
ease (Ib–IIa), randomized studies designed to show this magni-
tude of benefit in all NSCLCs required 10 times the number of 
patients. Despite the obvious limitations of a retrospective study 
of a less-common lung cancer, this study concludes that not all 
sarcomatoid carcinomas of the lung are chemotherapy refrac-
tory. As the prognosis after relapse of sarcomatoid carcinoma is 
poor, all attempts should be made to prevent or at least delay the 
time to relapse. Limitations of available data, combined with 
our data, are such that therapeutic nihilism is not warranted. 
In patients with resectable sarcomatoid carcinoma of the lung, 
neoadjuvant or adjuvant chemotherapy should be considered.
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